ICU Medical, Inc. — Q1 2012 Form 10-Q
Business context and reporting period. The filing covers the three months ended March 31, 2012. ICU Medical develops, manufactures and sells medical devices for infusion therapy, critical care and oncology. Results are unaudited; the company reports one business segment.
Financial results and liquidity
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Total revenue | $75.5 million | $71.5 million | Up 5.7% |
| Gross profit / margin | $35.0 million / 46% | $34.6 million / 48% | Margin down about 2 percentage points |
| Operating income / margin | $11.4 million / 15% | $12.2 million / 17% | Down 6.8% |
| Net income | $7.6 million | $8.1 million | Down 5.8% |
| Diluted EPS | $0.53 | $0.57 | Down $0.04 |
| Cash provided by operations | $18.3 million | $15.2 million | Up $3.2 million |
At March 31, cash and cash equivalents were $122.1 million and investment securities were $61.5 million, totaling $183.6 million, up $23.6 million from year-end. Current assets were $276.0 million and current liabilities $25.4 million. The balance sheet reports no debt line item. Q1 investing activities used $4.9 million, including $3.6 million of capital expenditures; financing activities provided $8.4 million, mainly from employee stock issuances and option exercises.
Material changes and management commentary
- Infusion therapy revenue increased 10% to $51.0 million, led by higher CLAVE and custom infusion set sales. Oncology sales rose 30% to $6.4 million. Critical care sales fell 14% to $13.6 million amid competition, lower unit volumes and price reductions.
- Gross margin declined due primarily to manufacturing inefficiencies and critical-care price reductions, each cited as contributing about one percentage point.
- SG&A fell to $20.9 million from $22.9 million. The prior-year quarter included a $2.0 million Long-Term Retention Plan expense. R&D rose to $2.7 million from $2.1 million, mainly reflecting higher project costs.
- Q1 2011 included a $2.5 million legal-settlement credit in operating expenses, which also makes the year-over-year comparison less favorable for 2012.
- Hospira represented 42% of Q1 2012 revenue, versus 41% in Q1 2011. Hospira also accounted for 31% of accounts receivable at quarter-end.
Outlook, risks and contingencies
- Management expected modest 2012 increases in infusion therapy and other domestic sales, moderate international growth, significant oncology growth, and lower critical-care sales. These expectations were expressly subject to uncertainty.
- Management estimated 2012 SG&A at 26.5%–27.0% of revenue, R&D at 2.5%–3.0%, an effective tax rate of about 35%, and capital expenditures of $13–$18 million.
- Management believed available cash, investments and expected operating cash flow would fund operations for at least the next 12 months. The company had $28.1 million remaining under its $40.0 million stock-repurchase authorization and made no repurchases in Q1.
- Key risks include substantial Hospira/customer concentration, competition and price pressure in critical care and CLAVE markets, dependence on successful product development and sales growth, manufacturing issues, and foreign-exchange and raw-material exposure.
- Patent litigation against RyMed remained pending. A jury had found infringement and patent validity in 2010; a new trial on one infringement issue and a bench trial on remaining issues were scheduled for May 2012. Management said other legal matters were not expected to materially affect results.
Important facts for investors to verify
- Whether Hospira remains a stable customer and distribution relationship given its 42% share of revenue and significant share of receivables.
- Whether critical-care competition and pricing continue to pressure sales and gross margins, and whether projected oncology and infusion growth materializes.
- The outcome and potential financial impact, if any, of the RyMed patent litigation.
- Actual 2012 capital spending, operating expense ratios, cash generation and any share repurchases compared with management estimates.
- Investment portfolio liquidity and risks: $61.5 million of available-for-sale securities, all reported as investment grade; the filing also notes interest-rate, currency and resin-price sensitivities.